Medtronic Proceeds from issuance of shares decreased by 12.0% to $95.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.7%, from $89.00M to $95.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from issuance of shares shows relatively stable performance with a 1.7% CAGR.
An increase suggests capital raising for growth or balance sheet strengthening, while a decrease is typical for mature companies focusing on buybacks.
Cash inflows generated from the issuance of common or preferred stock, including exercises of employee stock options or...
Standard line item for all publicly traded companies.
financing_proceeds_from_issuance_or_sale_of_equity| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $160.00M | $111.00M | $42.00M | $191.00M | $85.00M | $43.00M | $106.00M | $60.00M | $99.00M | $77.00M | $155.00M | $0.00 | $78.00M | $89.00M | $166.00M | $145.00M | $108.00M | $95.00M |
| QoQ Change | — | -30.6% | -62.2% | +354.8% | -55.5% | -49.4% | +146.5% | -43.4% | +65.0% | -22.2% | +101.3% | -100.0% | — | +14.1% | +86.5% | -12.7% | -25.5% | -12.0% |
| YoY Change | — | — | — | — | -46.9% | -61.3% | +152.4% | -68.6% | +16.5% | +79.1% | +46.2% | -100.0% | -21.2% | +15.6% | +7.1% | — | +38.5% | +6.7% |